The Peripheral Myeloid Expansion Driven by Murine Cancer Progression Is Reversed by Radiation Therapy of the Tumor

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Crittenden, Marka R ^a,b   Savage, Talicia ^a   Cottam, Benjamin ^a   Bahjat, Keith S ^a   Redmond, William L ^a   Bambina, Shelly ^a   Kasiewicz, Melissa ^a   Newell, Pippa ^a,b   Jackson, Andrew M ^c   Gough, Michael J ^a  

^a PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^b Oregon Clinic   (United States)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE VACCINE; SERYLPROLYLSERYLTYROSYLVALYLTYROSYLHISTIDINYLGLUTAMINYLPHENYLALANINE A5; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL COUNT; CELL EXPANSION; CELL LINEAGE; CONTROLLED STUDY; IMMUNE RESPONSE; LISTERIA MONOCYTOGENES; LUNG METASTASIS; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; SPLEEN; T LYMPHOCYTE; TUMOR RECURRENCE;

ADENOCARCINOMA; ANIMALS; ANTIGENS, NEOPLASM; CELL COUNT; CELL PROLIFERATION; FEMALE; GAMMA RAYS; IMMUNE TOLERANCE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MYELOID CELLS; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; SKIN; SPLEEN; T-LYMPHOCYTES; TRANSPLANTATION, HETEROTOPIC; TUMOR BURDEN;

EID: 84880796356     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069527     Document Type: Article

References (54)

1. Lin EY, Nguyen AV, Russell RG, Pollard JW, (2001) Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193: 727-740.
2. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, et al. (2006) Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 66: 11238-11246.
3. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, et al. (2011) Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. Cancer Discovery 1: 54-67.
4. Gabrilovich DI, Bronte V, Chen SH, Colombo MP, Ochoa A, et al. (2007) The terminology issue for myeloid-derived suppressor cells. Cancer Res 67: 425; author reply 426.
5. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, et al. (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58: 49-59.
6. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, et al. (2008) Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111: 4233-4244.
7. Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, et al. (2012) Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21: 822-835.
8. Gabrilovich DI, Nagaraj S, (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nature reviews Immunology 9: 162-174.
9. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S, (2007) Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 179: 977-983.
10. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, et al. (2010) 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Research 70: 3052-3061.
11. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM, (2005) Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clinical cancer research: an official journal of the American Association for Cancer Research 11: 6713-6721.
12. Sinha P, Clements VK, Ostrand-Rosenberg S, (2005) Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 174: 636-645.
13. Makarenkova VP, Bansal V, Matta BM, Perez LA, Ochoa JB, (2006) CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J Immunol 176: 2085-2094.
14. Aslakson CJ, Miller FR, (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Research 52: 1399-1405.
15. Priebe TS, Atkinson EN, Pan BF, Nelson JA, (1992) Intrinsic resistance to anticancer agents in the murine pancreatic adenocarcinoma PANC02. Cancer Chemother Pharmacol 29: 485-489.
16. Seung SK, Curti BD, Crittenden M, Walker E, Coffey T, et al. (2012) Phase 1 Study of Stereotactic Body Radiotherapy and Interleukin-2'ÄîTumor and Immunological Responses. Science Translational Medicine 4: 137ra174.
17. Brockstedt DG, Giedlin MA, Leong ML, Bahjat KS, Gao Y, et al. (2004) Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proceedings of the National Academy of Sciences of the United States of America 101: 13832-13837.
18. Bunt SK, Yang L, Sinha P, Clements VK, Leips J, et al. (2007) Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 67: 10019-10026.
19. Kowanetz M, Wu X, Lee J, Tan M, Hagenbeek T, et al. (2010) Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proceedings of the National Academy of Sciences of the United States of America 107: 21248-21255.
20. Tamai H, Watanabe S, Zheng R, Deguchi K, Cohen PA, et al. (2008) Effective treatment of spontaneous metastases derived from a poorly immunogenic murine mammary carcinoma by combined dendritic-tumor hybrid vaccination and adoptive transfer of sensitized T cells. Clinical Immunology 127: 66-77.
21. Kaminski JM, Shinohara E, Summers JB, Niermann KJ, Morimoto A, et al. (2005) The controversial abscopal effect. Cancer treatment reviews 31: 159-172.
22. Crittenden MR, Cottam B, Savage T, Nguyen C, Newell P, et al. (2012) Expression of NF-kappaB p50 in Tumor Stroma Limits the Control of Tumors by Radiation Therapy. PLoS ONE 7: e39295.
23. Bronte V, Chappell DB, Apolloni E, Cabrelle A, Wang M, et al. (1999) Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol 162: 5728-5737.
24. Bunt SK, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S, (2006) Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. Journal of Immunology 176: 284-290.
25. Slansky JE, Rattis FM, Boyd LF, Fahmy T, Jaffee EM, et al. (2000) Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 13: 529-538.
26. Pamer EG, Harty JT, Bevan MJ, (1991) Precise prediction of a dominant class I MHC-restricted epitope of Listeria monocytogenes. Nature 353: 852-855.
27. Dolcetti L, Peranzoni E, Ugel S, Marigo I, Fernandez Gomez A, et al. (2010) Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. European Journal of Immunology 40: 22-35.
28. Abe F, Dafferner AJ, Donkor M, Westphal SN, Scholar EM, et al. (2009) Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice. Cancer Immunol Immunother.
29. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, et al. (2007) Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 67: 9518-9527.
30. Donkor MK, Lahue E, Hoke TA, Shafer LR, Coskun U, et al. (2009) Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells. Int Immunopharmacol 9: 937-948.
31. Pang G, Couch L, Batey R, Clancy R, Cripps A, (1994) GM-CSF, IL-1 alpha, IL-1 beta, IL-6, IL-8, IL-10, ICAM-1 and VCAM-1 gene expression and cytokine production in human duodenal fibroblasts stimulated with lipopolysaccharide, IL-1 alpha and TNF-alpha. Clinical and experimental immunology 96: 437-443.
32. Fibbe WE, Daha MR, Hiemstra PS, Duinkerken N, Lurvink E, et al. (1989) Interleukin 1 and poly(rI).poly(rC) induce production of granulocyte CSF, macrophage CSF, and granulocyte-macrophage CSF by human endothelial cells. Experimental hematology 17: 229-234.
33. Suzuki A, Takahashi T, Okuno Y, Tsuyuoka R, Fukumoto M, et al. (1992) IL-1 production as a regulator of G-CSF and IL-6 production in CSF-producing cell lines. British journal of cancer 65: 515-518.
34. Fibbe WE, van Damme J, Billiau A, Voogt PJ, Duinkerken N, et al. (1986) Interleukin-1 (22-K factor) induces release of granulocyte-macrophage colony-stimulating activity from human mononuclear phagocytes. Blood 68: 1316-1321.
35. Herrmann F, Oster W, Meuer SC, Lindemann A, Mertelsmann RH, (1988) Interleukin 1 stimulates T lymphocytes to produce granulocyte-monocyte colony-stimulating factor. The Journal of clinical investigation 81: 1415-1418.
36. Waight JD, Hu Q, Miller A, Liu S, Abrams SI, (2011) Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLoS ONE 6: e27690.
37. DuPre SA, Hunter KW Jr, (2007) Murine mammary carcinoma 4T1 induces a leukemoid reaction with splenomegaly: association with tumor-derived growth factors. Experimental and molecular pathology 82: 12-24.
38. Xu Y, Methuku N, Coimbatore P, Fitzgerald T, Huang Y, et al. (2012) Immunogenicity of an Inactivated Monovalent 2009 Influenza A (H1N1) Vaccine in Patients Who Have Cancer. The oncologist 17: 125-134.
39. Seung LP, Rowley DA, Dubey P, Schreiber H, (1995) Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proceedings of the National Academy of Sciences of the United States of America 92: 6254-6258.
40. Sarkar D, Srivastava MK, Zhu L, Harris-White M, Kar U, et al. (2012) Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer. PLoS ONE 7: e40677.
41. Serafini P, Meckel K, Kelso M, Noonan K, Califano J, et al. (2006) Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 203: 2691-2702.
42. De Santo C, Serafini P, Marigo I, Dolcetti L, Bolla M, et al. (2005) Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proceedings of the National Academy of Sciences of the United States of America 102: 4185-4190.
43. Kusmartsev S, Cheng F, Yu B, Nefedova Y, Sotomayor E, et al. (2003) All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Research 63: 4441-4449.
44. Shi C, Hohl TM, Leiner I, Equinda MJ, Fan X, et al. (2011) Ly6G+ neutrophils are dispensable for defense against systemic Listeria monocytogenes infection. Journal of Immunology 187: 5293-5298.
45. Hannan R, Zhang H, Wallecha A, Singh R, Liu L, et al. (2012) Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer. Cancer immunology, immunotherapy: CII.
46. Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, et al. (2004) External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Research 64: 4328-4337.
47. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, et al. (2006) Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. The Journal of experimental medicine 203: 1259-1271.
48. Kwilas AR, Donahue RN, Bernstein MB, Hodge JW, (2012) In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer. Frontiers in oncology 2: 104.
49. Takeshima T, Chamoto K, Wakita D, Ohkuri T, Togashi Y, et al. (2010) Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Research 70: 2697-2706.
50. Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, et al. (2005) Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 11: 728-734.
51. Gough MJ, Crittenden MR, Sarff M, Pang P, Seung SK, et al. (2010) Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice. J Immunother 33: 798-809.
52. Yokouchi H, Yamazaki K, Chamoto K, Kikuchi E, Shinagawa N, et al. (2008) Anti-OX40 monoclonal antibody therapy in combination with radiotherapy results in therapeutic antitumor immunity to murine lung cancer. Cancer Sci 99: 361-367.
53. Shi W, Siemann DW, (2006) Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment. Anticancer research 26: 3445-3453.
54. Chi CH, Wang YS, Yang CH, Chi KH, (2010) Neoadjuvant immunotherapy enhances radiosensitivity through natural killer cell activation. Cancer biotherapy & radiopharmaceuticals 25: 39-45.